These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 11223556

  • 1. [HBME-1 immunostaining in thyroid pathology].
    Rigau V, Martel B, Evrard C, Rousselot P, Galateau-Salle F.
    Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
    [Abstract] [Full Text] [Related]

  • 2. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.
    Miettinen M, Kärkkäinen P.
    Virchows Arch; 1996 Nov; 429(4-5):213-9. PubMed ID: 8972756
    [Abstract] [Full Text] [Related]

  • 3. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma.
    Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA.
    Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical localization of acidic and basic fibroblast growth factors in human benign and malignant thyroid lesions.
    Kodama M, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S.
    Jpn J Clin Oncol; 1994 Apr; 24(2):66-73. PubMed ID: 7512670
    [Abstract] [Full Text] [Related]

  • 5. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
    Ziadi S, Trimeche M, Zermani R, Elmay A, Baltagi-Ben Jilani S.
    Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL.
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [Abstract] [Full Text] [Related]

  • 7. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
    Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A.
    Anticancer Res; 2005 Apr; 25(1A):179-82. PubMed ID: 15816536
    [Abstract] [Full Text] [Related]

  • 8. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD, Wang LJ, Yao HT, Li J, Ding W, Yan LP.
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM, Ibrahim TR.
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS.
    Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G.
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [Abstract] [Full Text] [Related]

  • 12. Blood group antigens in differentiated thyroid neoplasms.
    González-Cámpora R, García-Sanatana JA, Jordà i Heras MM, Salaverri CO, Vázquez-Ramírez FJ, Argueta-Manzano OE, Galera-Davidson H.
    Arch Pathol Lab Med; 1998 Nov; 122(11):957-65. PubMed ID: 9822123
    [Abstract] [Full Text] [Related]

  • 13. Patterns of basement membrane laminin distribution in nonneoplastic and neoplastic thyroid tissue.
    Campo E, Perez M, Charonis AA, Axiotis CA, Merino MJ.
    Mod Pathol; 1992 Sep; 5(5):540-6. PubMed ID: 1344818
    [Abstract] [Full Text] [Related]

  • 14. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
    Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M.
    Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
    [Abstract] [Full Text] [Related]

  • 15. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
    Mataraci EA, Ozgüven BY, Kabukçuoglu F.
    Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
    [Abstract] [Full Text] [Related]

  • 16. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
    Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C.
    Anticancer Res; 2000 Mar; 20(1A):311-6. PubMed ID: 10769673
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
    Mai KT, Ford JC, Yazdi HM, Perkins DG, Commons AS.
    Pathol Res Pract; 2000 Mar; 196(8):533-40. PubMed ID: 10982016
    [Abstract] [Full Text] [Related]

  • 18. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
    Lamba Saini M, Weynand B, Rahier J, Mourad M, Hamoir M, Marbaix E.
    Diagn Pathol; 2015 Apr 18; 10():32. PubMed ID: 25907675
    [Abstract] [Full Text] [Related]

  • 19. Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma.
    Takeyama H, Hosoya T, Sakurai K, Mori Y, Watanabe M, Kisaki H, Ohno T.
    Cancer Res; 1996 Apr 15; 56(8):1817-22. PubMed ID: 8620498
    [Abstract] [Full Text] [Related]

  • 20. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
    Bogdańska M, Górnicka B, Ziarkiewicz-Wróblewska B, Koperski L, Morton M, Wasiutyński A.
    Endokrynol Pol; 2006 Apr 15; 57(4):314-9. PubMed ID: 17006830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.